Lykalyfaxone Uses

How times a day do you take this medicine?
sponsored

Lykalyfaxone indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Treatment of the following infections when caused by susceptible aerobic organisms.

Lower respiratory tract infections caused by Streptococcus pneumoniae, Streptococcus species (excluding enterococci), methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae, H. parainfluenzae, Klebsiella species (including K. pneumoniae), Escherichia coli, Enterobacter aerogenes, Proteus mirabilis and Serratia marcescens.

Skin and skin structure infections caused by methicillin-sensitive Staphylococcus aureus, methicillin-sensitive Staphylococcus epidermidis, Streptococcus Group B, Streptococcus Group G, Streptococcus pyogenes, Streptococcus viridans, Streptococcus species (excluding enterococci), Peptostreptococcus species, Escherichia coli, Enterobacter cloacae, Klebsiella species (including K. pneumoniae, K. oxytoca), Proteus mirabilis, Morganella morganii and Serratia marcescens.

Urinary tract infections (complicated and uncomplicated) caused by E. coli, Proteus mirabilis, Proteus vulgaris, M. morganii and Klebsiella species (including K. pneumoniae).

Uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including penicillinase- and nonpenicillinase-producing strains.

Bacterial septicemia caused by Streptococcus pneumoniae, E. coli and H. influenzae.

Bone infections caused by methicillin-sensitive S. aureus, methicillin-sensitive S. epidermidis, Stretococcus Group B, Streptococcus pneumoniae, Streptococcus species (excluding enterococci), E. coli, Enterobacter species, P. mirabilis and K. pneumoniae.

Joint infections caused by methicillin-sensitive S. aureus, Streptococcus pneumoniae, Streptococcus species (excluding enterococci), E. coli, P. mirabilis, K. pneumoniae and Enterobacter species.

Meningitis: The initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by Haemophilus influenzae type b, Neisseria meningitidis, Streptococcus pneumoniae or Enterobacteriaceae pending culture and sensitivity results.

Surgical Prophylaxis: The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated and patients undergoing coronary artery bypass surgery. Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted.

Susceptibility Testing: Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.

Lykalyfaxone description

sponsored

Each vial contains ceftriaxone sodium 1.19 g equivalent to ceftriaxone 1 g.

Lykalyfaxone is a sterile, semisynthetic, broad spectrum cephalosphorin antibiotic for IV or IM administration. It contains approximately 83 mg (3.6mEq) of sodium per g of ceftriaxone activity.

Ceftriaxone sodium is disodium (6R,7R)-[[(2Z)-2-aminothiazol-4-yl)methoxyimino)acetyl]amino]-3-[[(2-methyl-6-oxido-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)sulphanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 3,5 hydrate.

The chemical formula of ceftriaxone sodium is C18H16N8Na2O7S3·3½H2O. It has a calculated molecular weight of 661.59 (CAS Registry Number: 104376-79-6).

Ceftriaxone sodium is a white or yellowish crystalline powder which is very soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 5% aqueous solution is approximately 6-8. Ceftriaxone sodium solutions may be light yellow to amber-colored in color.

Lykalyfaxone dosage

sponsored

Recommended Daily Dose: Adult: 1-2 g once a day or in equally divided doses twice a day depending on the type and severity of the infection. The lower dose would be appropriate for less severe infections.

Uncomplicated Gonococcal Infections: As a single IM dose of 250 mg.

Preoperative Use (Surgical Prophylaxis) in Cardiovascular Surgery, Biliary Tract Surgery in High Risk Patients and in Vaginal and Abdominal Hysterectomy: As a single dose of 1 g administered 30 min to 2 hrs before surgery.

Serious Miscellaneous Infections: Children: Recommended Total Daily Dose: 50-75 mg/kg (not to exceed 2 g), given once per day or in divided doses every 12 hrs. In meningitis, the dose should be divided and administered every 12 hrs.

Generally, ceftriaxone therapy should be continued for at least 2 days after the signs ans symptoms of infection have disappeared. The usual duration is 4-14 days. In special conditions eg, endocarditis, osteomyelitis, infected joints etc, treatment may be continued for a longer duration. Prolonged therapy results in a higher incidence of adverse effects particularly diarrhea, rash, eosinophilia, elevated liver enzymes and to a lesser extent neutropenia.

When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.

No dosage adjustment is necessary for patients with impairment of hepatic function; however, blood levels should be monitored in patients with severe renal impairment (eg, dialysis patients) and in patients with both renal and hepatic dysfunction. Serum levels should not exceed 280 mcg/mL.

Administration: Lykalyfaxone contains no antimicrobial agent. Product is for single use in 1 patient only. Discard any residue.

Lykalyfaxone may be administered IV or IM.

The use of freshly prepared solution is recommended. These retain their efficacy for at least 6 hrs at room temperature (or 24 hrs ar 2-8oC). The solutions are yellowish in color. To reduce microbiological hazard, use as soon as practicable after dilution. If storage is necessary, hold at 2-8oC for not more than 24 hrs.

Lykalyfaxone should not be added to solutions containing calcium eg, Hartmann's solution and Ringer's solution. Lykalyfaxone should also not be mixed with or piggybacked into solutions containing other antimicrobial drugs or into diluent solutions other than those listed as follows, owing to possible incompatibility. Specifically, the literature reports that ceftriaxone is incompatible with amsacrine, vancomycin, fluconazole and aminoglycosides.

Intramuscular Injection: Lykalyfaxone 1 g in 3.5 mL of 1 % lignocaine solution and administered by deep intragluteal injection. It is recommended that no more than 1 g be injected on either side. The lignocaine solution must never be administered IV. Lykalyfaxone should be injected well into the body of a relatively large muscle mass.

Intramuscular injection without lignocaine solution is painful.

Intravenous Injection: Lykalyfaxone 1 g in 10 mL water for injections, and then administered by direct IV injection lasting 2-4 min.

Intravenous Infusion: Lykalyfaxone 2 g is dissolved in approximately 40 mL of one of the following infusion solutions: Sodium chloride 0.9%m, sodium chloride 0.45% + glucose 2.5%, glucose 5%, glucose 10%, dextran 70.6% in glucose 5%.

The infusion should be given over a period of at least 30 min.

Lykalyfaxone interactions

sponsored

Ceftriaxone does not contain an N-methylthiotetrazole moiety which has been associated with significant impairment of Vitamin K-dependent coagulation by some other cephalosporins. Probenecid does not cause clinically significant changes in the elimination of ceftriaxone. Concomitant use does not confer a therapeutic benefit.

In an in vitro study, antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone.

Effects on Laboratory Tests: In patients treated with ceftriaxone the Coombs' test may become false-positive. Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosemia.

Likewise, non-enzymatic methods for the glucose determination in urine may give false-positive results. For this reason, urine-glucose determination during therapy with ceftriaxone should be done enzymatically.

Lykalyfaxone side effects

Ceftriaxone is generally well-tolerated. In clinical trials, the following adverse reactions, which were considered to be related to ceftriaxone therapy or of uncertain etiology, were observed. Their incidence was somewhat higher in children and with higher doses.

Local Effects: Infrequent pain, induration or tenderness at the site of injection, ess frequently reported was phlebitis after IV administration. Local reactions were increased if water was used as the diluent instead of lignocaine.

Hypersensitivity: Infrequent rash. Less frequently reported were pruritus, fever or chills, severe dermatitis including exfoliative erythroderma, anaphylaxis, erythema multiforme, urticaria, exanthema, allergic dermatitis.

Hematological: Occasional eosinophilia, thrombocytosis and leukopenia.

Less frequently reported hemolytic anemia, neutropenia, lymphopenia, granulocytopenia, thrombocytopenia and prolongation of PT and bleeding. In very rare cases, agranulocytosis has been reported.

Gastrointestinal: Occasional diarrhea. Less frequently reported were nausea or vomiting, stomatitis, glossitis and dysgeusia. Incidence of diarrhea was higher in women and children. Pseudomembranous colitis has been reported rarely.

Hepatic: Occasional elevations of serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT). Less frequently reported were elevations of alkaline phosphatase and bilirubin. Shadows, which have been mistaken for gallstones, have been detected on sonograms of the gallbladder; usually following doses higher than the standard recommended dose. These shadows are, however, precipitates of calcium ceftriaxone which disappear on completion or discontinuation of ceftriaxone therapy. Rarely have these findings been associated with symptoms. In symptomatic cases, conservative non surgical management is recommended. Discontinuation of ceftriaxone treatment in symptomatic cases should be at the discretion of the clinician.

Renal: Infrequent elevations of the serum urea. Less frequently reported were elevations of creatinine and the presence of casts in the urine. Crystalluria and oliguria have been reported very rarely.

Renal adverse effects were somewhat more frequent in the elderly.

Central Nervous System: Headache or dizziness were reported occasionally.

Genitourinary: Moniliasis or vaginitis were reported occasionally.

Miscellaneous: Diaphoresis, flushing and fever were reported occasionally.

Other rarely observed adverse reactions include leukocytosis, lymphocytosis, monocytosis, basophilia, jaundice, glycosuria, hematuria, bronchospasm, edema, shivering, serum sickness, abdominal pain, flatulence, dyspepsia, palpitations and epistaxis.

Isolated cases of severe cutaneous reactions (Stevens Johnson syndrome or Lyell's syndrome/toxic epidermal necrolysis) have been reported.

Cases of fatal reactions with calcium-ceftriaxone precipitates in lung and kidney in neonates and premature infants have been described. In some cases the infusion lines and times of administration of ceftriaxone and calcium-containing solutions differed. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing solutions or products, even via different infusion lines.

Lykalyfaxone contraindications

Hypersensitivity to cephalosporin class of antibiotics or a major allergy to penicillin (anaphylaxis, angioneurotic edema, urticaria).

Lignocaine should not be used as diluent for IM injection in patients who are hypersensitive to lignocaine.

Lykalyfaxone must not be administered with calcium-containing solutions in newborns because of the risk of precipitation of ceftriaxone-calcium salt. Cases of fatal reactions with calcium-ceftriaxone precipitates in lung and kidney in newborns have been described. In some cases, the infusion lines and times of administration of ceftriaxone and calcium-containing solution differed. Therefore, Lykalyfaxone and IV calcium-containing solutions must not be administered within 48 hrs of each other in newborns.

Hyperbilirubinemic newborns and preterm newborns should not be treated with ceftriaxone.

In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a possible risk of bilirubin encephalopathy in these patients.



Active ingredient matches for Lykalyfaxone:

Ceftriaxone Na in Vietnam.


Unit description / dosage (Manufacturer)Price, USD
LykaLyfaxone 1 g x 1 Bottle

List of Lykalyfaxone substitutes (brand and generic names):

Lafoncef 1 g x 1 Bottle
Merausin 1 g x 1 Bottle
Meticef 1 g x 1 Bottle 20 mL in 1 tube nöôùc caát 5 mL
MGP Axinex 1 g x 1 Bottle in 1 Bottle nöôùc pha tieâm 10 mL
Milcerof 1 g x 10 Bottle
NextChem Ceftriaxone / + 10 mL diluent 1 g x 1's
Norcephin 1 g x 1's
Noxoram 1 g x 1's (Alkem)$ 15.00
Pacefin 1 g x 1 Bottle
Panjecxone / vial 1 g x 10's
Paroladin 1 g x 1 Bottle
Paroladin 1 g x 10 Bottle
Penceftin 1000 1 g x 1 Bottle
Phil Pharmawealth/Aurobindo Ceftriaxone Sodium 1 g x 1's
Phil Pharmawealth/Aurobindo Ceftriaxone Sodium 500 mg x 1's
Pletrox 1 g x 10 Bottle
Rowject 1 g x 10 Bottle
Samaxon 1 g x 1 Bottle in 1 tube nöôùc caát 10 mL
SamChunDang Axon 1 g x 10 Bottle
Sanaphine 1 g x 1 Bottle in 5 mL dung mobi pha tieГўm
Santoxon 1 g x 10 Bottle
Seltroz / vial 1 g x 1's
Seofen 1 g x 10 Bottle
Setrionac 1 g x 10 Bottle
Sodicef 1 g x 10 Bottle
Tevaxone 1 g/1 vial x 25 Bottle
Toptrixone 1 g x 10 Bottle
Travilan DR. PD 1 g x 1 Bottle boät in 1 tube dung mobi pha tieâm 3.5 mL
Travilan DR. PD 1 g x 1 Bottle boät in 1 tube nöôùc caát pha tieâm 10 mL
Travilan DR. PD 1 g x 10 Bottle boät in 10 tube nöôùc caát pha tieâm 10 mL
TV-Ceftri 1 g x 1 Bottle boät in 5 mL nöôùc caát
Ty-oxone 1 g x 1's
Ty-oxone / vial 250 mg x 1's
Ty-oxone 500 mg x 1's
Ukcef 1 g x 10 Bottle
Vidtria 1 g x 1 Bottle
Vidtria 1 g x 10 Bottle
Yuxon 1 g x 10 Bottle

Reviews

The results of a survey conducted on ndrugs.com for Lykalyfaxone are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lykalyfaxone. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 28 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved